Redeye provides a more in-depth review of Episurf Medical’s Q2 report. Since the company’s sales came in lower than expected, we made some downward adjustments to our estimates for the short and medium-term sales forecasts. We revise our base case valuation to SEK1.3 (SEK1.4) per share.
LÄS MER